🚨 J&J Just Agreed to Buy Eye-Drug Biotech Ollin for $2.2 Billion Upfront
J&J will pay $2.2bn upfront, plus up to $1.125bn in milestones, for Ollin Biosciences and its Phase 3 eye-disease antibody OLN324.

Johnson & Johnson has agreed to buy Ollin Biosciences for $2.2 billion in cash upfront, with up to about $1.125 billion more in milestone payments on top. The deal was announced on Monday morning, US time (Reuters via Yahoo Finance).
If every milestone is hit, the total comes to roughly $3.3 billion. That is a lot of money for a company founded in 2023.
What J&J is really buying is one drug: OLN324, an eye-disease antibody already in Phase 3 trials.
⚡ What Happened
- J&J signed a definitive agreement to acquire Ollin, a Texas-based, clinical-stage biotech backed by ARCH Venture Partners and Mubadala Capital (Reuters via Yahoo Finance).
- The terms are $2.2 billion upfront plus up to $1.125 billion in regulatory and commercial milestones (Newsquawk).
- In a side deal, Blackstone Life Sciences will pay J&J $750 million over several years to fund OLN324’s Phase 3 programme, in return for milestone payments and single-digit royalties if the drug sells (Investing.com).
- J&J expects the deal to close before the end of 2026, subject to regulatory approval.
🧠 Why It Matters
OLN324 is a bispecific antibody: one molecule that hits two targets. Here they are VEGF and angiopoietin-2, two signals that drive leaky, overgrown blood vessels in the retina (Investing.com).
It is being developed for wet age-related macular degeneration and diabetic macular edema, two of the biggest causes of vision loss. According to J&J, those conditions affect more than 40 million people worldwide.
You may have heard of this approach before. Roche’s Vabysmo, approved by the FDA in 2022, was the first bispecific antibody for the eye and blocks the same two pathways (Roche). So J&J is not betting on an untested idea. It is betting that it can beat an established rival, probably on how long each eye injection lasts.
The Blackstone money is the clever part. J&J gets a late-stage drug while someone else pays for a big slice of the most expensive trials. If you were wondering why private equity keeps turning up in pharma, this is how it works.
🔜 What To Watch
- Phase 3 data. None of this means much until OLN324 shows results against existing treatments.
- Regulatory sign-off before the year-end close.
- More pharma deal-making. Big drugmakers have cash to spend and patents expiring, and mid-sized biotech deals like this one are how they fill the gap.
Details on trial timelines and the drug’s origins are still emerging.
Sources
- Reuters via Yahoo Finance: J&J strikes $2.2 billion buyout deal for eye disease biotech Ollin Biosciences
- Newsquawk: J&J to acquire Ollin Biosciences and late-stage bispecific antibody
- Investing.com: Johnson & Johnson to acquire Ollin Biosciences for $2.2 billion
- MarketScreener: Johnson & Johnson to Acquire Ollin Biosciences for Up to $3.33 Billion
- Roche: FDA approves Vabysmo, the first bispecific antibody for the eye
❓ Quick answers
How much is Johnson & Johnson paying for Ollin Biosciences?
J&J is paying $2.2 billion upfront, with up to about $1.125 billion more in milestone payments, roughly $3.3 billion in total, according to the deal announced on 16 November 2026 and reported by Reuters.
What is OLN324?
OLN324 is Ollin's investigational bispecific antibody targeting VEGF and angiopoietin-2, in Phase 3 development for wet age-related macular degeneration and diabetic macular edema.
When will the J&J Ollin deal close?
J&J expects the acquisition to close before the end of 2026, subject to regulatory approvals and customary conditions.





